WO1997047318A1 - Utilisations d'un recepteur de chemokines en vue de l'inhibition de l'infection a vih-1 - Google Patents
Utilisations d'un recepteur de chemokines en vue de l'inhibition de l'infection a vih-1 Download PDFInfo
- Publication number
- WO1997047318A1 WO1997047318A1 PCT/US1997/010233 US9710233W WO9747318A1 WO 1997047318 A1 WO1997047318 A1 WO 1997047318A1 US 9710233 W US9710233 W US 9710233W WO 9747318 A1 WO9747318 A1 WO 9747318A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hiv
- cells
- agent
- binding
- chemokine
- Prior art date
Links
- 108050000299 Chemokine receptor Proteins 0.000 title claims abstract description 76
- 102000009410 Chemokine receptor Human genes 0.000 title claims abstract description 75
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 72
- 208000031886 HIV Infections Diseases 0.000 title abstract description 5
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims abstract description 131
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims abstract description 129
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 51
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 45
- 229920001184 polypeptide Polymers 0.000 claims abstract description 35
- 210000004027 cell Anatomy 0.000 claims description 236
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 172
- 230000027455 binding Effects 0.000 claims description 134
- 239000003795 chemical substances by application Substances 0.000 claims description 114
- 230000004927 fusion Effects 0.000 claims description 78
- 208000015181 infectious disease Diseases 0.000 claims description 74
- 102000019034 Chemokines Human genes 0.000 claims description 57
- 108010012236 Chemokines Proteins 0.000 claims description 57
- 238000000034 method Methods 0.000 claims description 54
- 108020004414 DNA Proteins 0.000 claims description 53
- 239000008194 pharmaceutical composition Substances 0.000 claims description 37
- 238000002165 resonance energy transfer Methods 0.000 claims description 37
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 claims description 33
- 101710121417 Envelope glycoprotein Proteins 0.000 claims description 33
- 102000039446 nucleic acids Human genes 0.000 claims description 29
- 108020004707 nucleic acids Proteins 0.000 claims description 29
- 150000007523 nucleic acids Chemical class 0.000 claims description 29
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims description 23
- 150000001413 amino acids Chemical class 0.000 claims description 23
- 239000003937 drug carrier Substances 0.000 claims description 23
- 239000003446 ligand Substances 0.000 claims description 16
- 102000053602 DNA Human genes 0.000 claims description 15
- 101800001690 Transmembrane protein gp41 Proteins 0.000 claims description 15
- 150000001875 compounds Chemical class 0.000 claims description 14
- 108700011778 CCR5 Proteins 0.000 claims description 13
- 241001465754 Metazoa Species 0.000 claims description 13
- 239000000975 dye Substances 0.000 claims description 13
- 230000009261 transgenic effect Effects 0.000 claims description 13
- 230000001965 increasing effect Effects 0.000 claims description 10
- 108010061299 CXCR4 Receptors Proteins 0.000 claims description 9
- 238000001727 in vivo Methods 0.000 claims description 8
- 108010041397 CD4 Antigens Proteins 0.000 claims description 7
- 108010038807 Oligopeptides Proteins 0.000 claims description 7
- 102000015636 Oligopeptides Human genes 0.000 claims description 7
- 102000000844 Cell Surface Receptors Human genes 0.000 claims description 5
- 108010001857 Cell Surface Receptors Proteins 0.000 claims description 5
- 239000002202 Polyethylene glycol Substances 0.000 claims description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- 108090000288 Glycoproteins Proteins 0.000 claims description 4
- 102000003886 Glycoproteins Human genes 0.000 claims description 4
- 102000016979 Other receptors Human genes 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 3
- 238000012546 transfer Methods 0.000 claims description 3
- 239000012634 fragment Substances 0.000 abstract description 10
- 102000001902 CC Chemokines Human genes 0.000 description 36
- 108010040471 CC Chemokines Proteins 0.000 description 36
- 238000003556 assay Methods 0.000 description 34
- 230000005764 inhibitory process Effects 0.000 description 26
- 230000003993 interaction Effects 0.000 description 24
- 108010043277 recombinant soluble CD4 Proteins 0.000 description 23
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 21
- 108010055166 Chemokine CCL5 Proteins 0.000 description 21
- 210000001744 T-lymphocyte Anatomy 0.000 description 20
- 241000700605 Viruses Species 0.000 description 20
- 102000005962 receptors Human genes 0.000 description 17
- 108020003175 receptors Proteins 0.000 description 17
- 230000001404 mediated effect Effects 0.000 description 16
- 235000001014 amino acid Nutrition 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 14
- 230000014509 gene expression Effects 0.000 description 14
- 230000034217 membrane fusion Effects 0.000 description 13
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 12
- 101710082513 C-X-C chemokine receptor type 4 Proteins 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 230000003472 neutralizing effect Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 230000010076 replication Effects 0.000 description 9
- 102100036664 Adenosine deaminase Human genes 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 description 6
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 description 6
- 108091008927 CC chemokine receptors Proteins 0.000 description 6
- 108060001084 Luciferase Proteins 0.000 description 6
- 239000005089 Luciferase Substances 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 235000013601 eggs Nutrition 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 208000030507 AIDS Diseases 0.000 description 5
- 230000002860 competitive effect Effects 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 241001529936 Murinae Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 101100225046 Schizosaccharomyces pombe (strain 972 / ATCC 24843) ecl2 gene Proteins 0.000 description 4
- 241000713311 Simian immunodeficiency virus Species 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 229910000389 calcium phosphate Inorganic materials 0.000 description 4
- 239000001506 calcium phosphate Substances 0.000 description 4
- 235000011010 calcium phosphates Nutrition 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 108700004025 env Genes Proteins 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 4
- UEUPDYPUTTUXLJ-UHFFFAOYSA-N 1-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane;octahydrochloride Chemical compound Cl.Cl.Cl.Cl.Cl.Cl.Cl.Cl.C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CN1CCCNCCNCCCNCC1 UEUPDYPUTTUXLJ-UHFFFAOYSA-N 0.000 description 3
- BYXHQQCXAJARLQ-ZLUOBGJFSA-N Ala-Ala-Ala Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O BYXHQQCXAJARLQ-ZLUOBGJFSA-N 0.000 description 3
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 3
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 3
- -1 CXCR Proteins 0.000 description 3
- 101000946926 Homo sapiens C-C chemokine receptor type 5 Proteins 0.000 description 3
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 3
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 101150030339 env gene Proteins 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 2
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 2
- 102100032366 C-C motif chemokine 7 Human genes 0.000 description 2
- 101710155834 C-C motif chemokine 7 Proteins 0.000 description 2
- 102100034871 C-C motif chemokine 8 Human genes 0.000 description 2
- 101710155833 C-C motif chemokine 8 Proteins 0.000 description 2
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 2
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 2
- 241000713711 Primate lentivirus group Species 0.000 description 2
- 230000010799 Receptor Interactions Effects 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 230000007910 cell fusion Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000010807 negative regulation of binding Effects 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 210000003101 oviduct Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- HHGYNJRJIINWAK-FXQIFTODSA-N Ala-Ala-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N HHGYNJRJIINWAK-FXQIFTODSA-N 0.000 description 1
- 241001128034 Amphotropic murine leukemia virus Species 0.000 description 1
- IJYZHIOOBGIINM-WDSKDSINSA-N Arg-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N IJYZHIOOBGIINM-WDSKDSINSA-N 0.000 description 1
- SPIPSJXLZVTXJL-ZLUOBGJFSA-N Asn-Cys-Ser Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(O)=O SPIPSJXLZVTXJL-ZLUOBGJFSA-N 0.000 description 1
- LRCIOEVFVGXZKB-BZSNNMDCSA-N Asn-Tyr-Tyr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O LRCIOEVFVGXZKB-BZSNNMDCSA-N 0.000 description 1
- LMIWYCWRJVMAIQ-NHCYSSNCSA-N Asn-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N LMIWYCWRJVMAIQ-NHCYSSNCSA-N 0.000 description 1
- 102100021277 Beta-secretase 2 Human genes 0.000 description 1
- 101710150190 Beta-secretase 2 Proteins 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 102100037853 C-C chemokine receptor type 4 Human genes 0.000 description 1
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 1
- 108010036239 CD4-IgG(2) Proteins 0.000 description 1
- 101100293276 Caenorhabditis elegans cra-1 gene Proteins 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 108010090461 DFG peptide Proteins 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 241000234271 Galanthus Species 0.000 description 1
- YTRBQAQSUDSIQE-FHWLQOOXSA-N Glu-Phe-Phe Chemical compound C([C@H](NC(=O)[C@H](CCC(O)=O)N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 YTRBQAQSUDSIQE-FHWLQOOXSA-N 0.000 description 1
- FMNHBTKMRFVGRO-FOHZUACHSA-N Gly-Asn-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CN FMNHBTKMRFVGRO-FOHZUACHSA-N 0.000 description 1
- IUZGUFAJDBHQQV-YUMQZZPRSA-N Gly-Leu-Asn Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O IUZGUFAJDBHQQV-YUMQZZPRSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- DLTCGJZBNFOWFL-LKTVYLICSA-N His-Tyr-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC2=CN=CN2)N DLTCGJZBNFOWFL-LKTVYLICSA-N 0.000 description 1
- 101000639987 Homo sapiens Stearoyl-CoA desaturase 5 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- HMDDEJADNKQTBR-BZSNNMDCSA-N Leu-His-Tyr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O HMDDEJADNKQTBR-BZSNNMDCSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- GCMWRRQAKQXDED-IUCAKERBSA-N Lys-Glu-Gly Chemical compound [NH3+]CCCC[C@H]([NH3+])C(=O)N[C@@H](CCC([O-])=O)C(=O)NCC([O-])=O GCMWRRQAKQXDED-IUCAKERBSA-N 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- PNDCUTDWYVKBHX-IHRRRGAJSA-N Met-Asp-Tyr Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 PNDCUTDWYVKBHX-IHRRRGAJSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000016978 Orphan receptors Human genes 0.000 description 1
- 108070000031 Orphan receptors Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- YRHRGNUAXGUPTO-PMVMPFDFSA-N Phe-Trp-Lys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CCCCN)C(=O)O)N YRHRGNUAXGUPTO-PMVMPFDFSA-N 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- UFKPDBLKLOBMRH-XHNCKOQMSA-N Ser-Glu-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)N)C(=O)O UFKPDBLKLOBMRH-XHNCKOQMSA-N 0.000 description 1
- MOQDPPUMFSMYOM-KKUMJFAQSA-N Ser-His-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CO)N MOQDPPUMFSMYOM-KKUMJFAQSA-N 0.000 description 1
- WLJPJRGQRNCIQS-ZLUOBGJFSA-N Ser-Ser-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O WLJPJRGQRNCIQS-ZLUOBGJFSA-N 0.000 description 1
- 102100033930 Stearoyl-CoA desaturase 5 Human genes 0.000 description 1
- MMTOHPRBJKEZHT-BWBBJGPYSA-N Thr-Cys-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(O)=O MMTOHPRBJKEZHT-BWBBJGPYSA-N 0.000 description 1
- MECLEFZMPPOEAC-VOAKCMCISA-N Thr-Leu-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N)O MECLEFZMPPOEAC-VOAKCMCISA-N 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- ZCPCXVJOMUPIDD-IHPCNDPISA-N Trp-Asp-Phe Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)N)C(O)=O)C1=CC=CC=C1 ZCPCXVJOMUPIDD-IHPCNDPISA-N 0.000 description 1
- QZOSVNLXLSNHQK-UWVGGRQHSA-N Tyr-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 QZOSVNLXLSNHQK-UWVGGRQHSA-N 0.000 description 1
- ZSXJENBJGRHKIG-UWVGGRQHSA-N Tyr-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 ZSXJENBJGRHKIG-UWVGGRQHSA-N 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- PZTZYZUTCPZWJH-FXQIFTODSA-N Val-Ser-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PZTZYZUTCPZWJH-FXQIFTODSA-N 0.000 description 1
- 230000010530 Virus Neutralization Effects 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 108091006004 biotinylated proteins Proteins 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 210000004970 cd4 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 108091008690 chemoreceptors Proteins 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 108010050848 glycylleucine Proteins 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000048160 human CCR5 Human genes 0.000 description 1
- 238000001597 immobilized metal affinity chromatography Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 108010084525 phenylalanyl-phenylalanyl-glycine Proteins 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 108010026333 seryl-proline Proteins 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 230000007501 viral attachment Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- Fusin 7-membrane-spanning, G-protein-linked superfamily, one of which (the LESTR orphan receptor) has been identified as the second receptor for TCLA HIV-l strains, and is now designated fusin (9) . Fusin is not known to be a ⁇ -chemokine receptor (7-9) . Summary of the Invention
- This invention provides a polypeptide having a sequence corresponding to the sequence of a portion of a chemokine receptor capable of inhibiting the fusion of HIV-l to CD4 + cells and thus infection of the cells.
- the chemokine receptor is C-C CKR-5.
- the CCKR-5 is also named as CCR5.
- the polypeptide comprises amino acids having a sequence of at least one extracellular domain of C-C CKR-5.
- the portion of a chemokine receptor comprises amino acid sequence MDYQVSSPIYDINYYTSEPCQKINVKQIAAR (SEQ ID NO: 5) .
- the portion comprises amino acid sequence HYAAAQWDFGNTMCQ (SEQ ID NO: 6) .
- the portion comprises amino acid sequence RSQKEGLHYTCSSHFPYSQYQFWKNFQTLKIV (SEQ ID NO: 7) .
- the portion comprises amino acid sequence QEFFGLNNCSSSNRLDQ (SEQ ID NO: 8) .
- the portion of the chemokine receptor C-C CKR-5 may comprise one or more of the above sequences.
- the polypeptides may contain part of the above illustrated sequences and still be capable of inhibiting HIV-l infection. The minimal number of amino acids sufficient to inhibit HIV-l infection may be determined by the RET or infection assays as described below.
- This invention also provides a pharmaceutical composition comprising effective amount of one or more of the above polypeptides and a pharmaceutically acceptable carrier.
- This invention also provides a polypeptide having a sequence corresponding to that of a portion of an HIV-l glycoprotein capable of specifically binding to the chemokine receptor C- C CKR-5.
- This invention provides a pharmaceutical composition comprising effective amount of one of more polypeptides having a sequence corresponding to the sequence of a portion of an HIV-l glycoprotein capable of specifically binding to the chemokine receptor C-C CKR-5 and a pharmaceutically acceptable carrier.
- This invention provides an antibody or a portion of an antibody capable of binding to a chemokine receptor on a CD4 + cell and inhibiting HIV-l infection of the cell.
- This invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising an effective amount of an antibody capable of binding to a chemokine receptor on a CD4 + cell and inhibiting HIV-l infection of the cell and a pharmaceutically acceptable carrier.
- This invention provides a method of treating an HIV-l infected subject comprising administering to the subject the above polypeptides, antibody and pharmaceutical compositions.
- This invention provides a method of reducing the likelihood of a subject from becoming infected by HIV-l comprising administering to the subject the above pharmaceutical compositions .
- This invention provides a method for inhibiting fusion of HIV-l to CD4" cells which comprises contacting CD4 + cells with a non-chemokine agent capable of binding to the chemokine receptor C-C CKR-5 in an amount and under conditions such that fusion of HIV-l to the CD4 + cells is inhibited.
- This invention provides a method for inhibiting HIV-l infection of CD4 + cells which comprises contacting CD4* cells with a non-chemokine agent capable of binding to the chemokine receptor C-C CKR-5 in an amount and under conditions such that fusion of HIV-l to the CD4 4 cells is inhibited, thereby inhibiting HIV-l infection of the cells.
- This invention provides a non-chemokine agent capable of binding to the chemokine receptor C-C CKR-5 and inhibiting HIV-l infection.
- This invention provides a molecule capable of binding to the chemokine receptor C-C CKR-5 and inhibiting HIV-l infection comprising a non-chemokine agent linked to a ligand capable of binding to a cell surface receptor of the CD4 * cells other than the chemokine receptor such that the binding of the non-chemokine agent to the chemokine receptor does not prevent the binding of the ligand to the other receptor.
- This invention provides a pharmaceutical composition comprising an amount of the above molecules effective to inhibit fusion of HIV-l to CD4 + cells and a pharmaceutically acceptable carrier.
- This invention also provides a molecule capable of binding to the chemokine receptor C-C CKR-5 and inhibiting fusion of HIV-l to CD4 + cells comprising a non-chemokine agent linked to a compound capable of increasing the in vivo half-life of the non-chemokine agent.
- This invention further provides a pharmaceutical composition
- a pharmaceutical composition comprising an amount of the molecule capable of binding to the chemokine receptor C-C CKR-5 and inhibiting HIV-l infection comprising a non-chemokine agent linked to a compound capable of increasing the in vivo half-life of the non-chemokine agent effective to inhibit fusion of HIV-l to CD4 + cells and a pharmaceutically acceptable carrier.
- This invention provides a method for reducing the likelihood of HIV-l infection in a subject comprising administering the above pharmaceutical compositions to the subject.
- This invention provides a method for treating HIV-l infection in a subject comprising administering the above pharmaceutical compositions to the subject.
- This invention provides a method for determining whether a non-chemokine agent is capable of inhibiting the fusion of HIV-l to a CD4 ⁇ C-C CKR-5 + cell which comprises: (a) contacting a CD4 + , C-C CKR-5* cell, which is labeled with a first dye, with a cell expressing an appropriate HIV-l envelope glycoprotein on its surface, which is labeled with a second dye, in the presence of excess of the agent under conditions permitting the fusion of the CD4 * and C-C CKR-5 * cell to the cell expressing the HIV-l envelope glycoprotein on its surface in the absence of an agent known to inhibit fusion of HIV-l to CD4 + , C-C CKR-5 + cell, the first and second dyes being selected so as to allow resonance energy transfer between the dyes; (b) exposing the product of step (a) to conditions which would result in resonance energy transfer if fusion has occurred; and (c) determining whether there is resonance energy transfer, the absence or reduction of transfer indicating
- This invention also provides a transgenic nonhuman animal which comprises an isolated DNA molecule encoding the chemokine receptor C-C CKR-5.
- this transgenic nonhuman animal further comprises an isolated DNA molecule encoding a sufficient portion of the CD4 molecule to permit binding the HIV-l envelope glycoprotein.
- This invention further provides a transgenic nonhuman animal which comprises an isolated DNA molecule encoding the chemokine receptor C-C CKR-5 and an isolated DNA molecule encoding fusin.
- this transgenic nonhuman animal further comprises an isolated DNA molecule encoding the full-length or portion of the CD4 molecule sufficient for binding the HIV-l envelope glycoprotein.
- This invention also provides transformed cells which comprise an isolated nucleic acid molecule encoding the chemokine receptor C-C CKR-5.
- his invention provides an agent capable of inhibiting HIV-l infection and capable of binding to a chemokine receptor without substantially affecting the said chemokine receptor's capability to bind to chemokines.
- Figure 1 Specificity, time course and stage of ⁇ -chemokine inhibition of HIV-l replication
- PM1 cells (1 xlO 6 ) were preincubated with RANTES + MIP- l ⁇ + MIP-1S (R/M ⁇ /M ⁇ ; lOOng/ml of each) for 24h (-24h) or 2h (-2h) , then washed twice with phosphate buffered saline (PBS) .
- HIV- 1 (BaL env-complemented) virus 50ng of p24; see legend to Table 1) was added for 2h, then the cells were washed and incubated for 48h before measurement of luciferase activity in cell lysates as described previously (10,11) .
- virus and R/Mo;/M ⁇ were added simultaneously to cells, and at the indicated time points (lh, 3h, etc) the cells were washed twice in PBS, resuspended in culture medium and incubated for 48h prior to luciferase assay.
- Time 0 represents the positive control, to which no ⁇ -chemokines were added.
- +2h represents the mixture of virus with cells for 2h prior to washing twice in PBS, addition of R/M ⁇ /M ⁇ and continuation of the culture for a further 48h before luciferase assay.
- Lanes 2 and 6) are negative controls (no virus) .
- Lanes 3 and 7 are negative controls (no virus) . All viral stocks used for the PCR assay were treated with DNAse for 30 min at 37°C, and tested for DNA contamination before use. After 2h, the cells were washed and resuspended in medium containing the same ⁇ -chemokines for a further 8h. DNA was then extracted from infected cells using a DNA/RNA isolation kit (US Biochemicals) . First round nested PCR was performed wi t h prime rs : U3 + , 5' -CAAGGCTACTTCCCTGATTGGCAGAACTACACACCAGG-3 ' (SEQ
- FIG. 2 HIV-l env-mediated membrane fusion of cells transiently expressing C-C CKR-5 Membrane fusion mediated by ⁇ -chemokine receptors expressed in HeLa cells was demonstrated as follows: Cells were transfected with control plasmid pcDNA3.1 or plasmid pcDNA3.1 -CKR constructs using lipofectin (Gibco BRL) . The pcDNA3.1 plasmid carries a T7-polymerase promoter and transient expression of ⁇ -chemokine receptors was boosted by infecting cells with lxlO 7 pfu of vaccinia encoding the T7-polymerase (vFT7.3) 4h post-lipofection (9) .
- FIG. 4 Flow cytometric analysis of the binding of sCD4- gp!20 complexes to (B)CCR5 " and (B)CCR5 LI.2 cells, a murine pre-B lymphoma line Cells are incubated for 15 min. with equimolar ( ⁇ 100nM) mixtures of sCD4 and biotinylated HIV-l ⁇ . FL gpl20 and then stained with a streptavidin- phycoerythrin conjugate, fixed with 2% paraformaldehyde, and analyzed by FACS. Cell number is plotted on the y-axis.
- the inhibitors were the CC chemokines MIP-13 or RANTES at the concentrations indicated on the x axis.
- the inhibition was measured using the RET assay, with the cell combinations indicated.
- This invention provides a polypeptide having a sequence corresponding to the sequence of a portion of a chemokine receptor capable of inhibiting the fusion of HIV-l to CD4* cells and thus infection of the cell.
- the chemokine receptor is C-C CKR-5 (CCR5) .
- the fragment comprises at least one extracellular domain of the chemokine receptor C-C CKR-5.
- the extracellular domain is the second extracellular loop of CCR5.
- the chemokine receptor is CCR3 or CKR-2b(31,32) .
- the sequence of a portion of the chemokine receptor includes the original amino acids or modified amino acids from the receptor, their derivatives and analogues. Such sequence should retain the ability to inhibit HIV-l infection. Sequences of fusin are also included.
- the portion of a chemokine receptor comprises amino acid sequence MDYQVSSPIYDINYYTSEPCQKINVKQIAAR (SEQ ID NO: 5) .
- the portion comprises amino acid sequence HYAAAQ DFGNTMCQ (SEQ ID NO: 6) .
- the portion comprises amino acid sequence RSQKEGLHYTCSSHFPYSQYQFWKNFQTLKIV (SEQ ID NO: 7) .
- the portion comprises amino acid sequence QEFFGLNNCSSSNRLDQ (SEQ ID NO: 8) .
- the portion of the chemokine receptor C-C CKR-5 may comprise one or more of the above sequences.
- the polypeptides may contain part of the above illustrated sequences and still be capable of inhibiting HIV-l infection. The minimal number of amino acids sufficient to inhibit HIV-l infection may be determined by the RET or infection assays as described below .
- polypeptides described above may be fusion molecules such that the fragments are linked to other molecules.
- the molecule is a CD4-based molecule.
- CD4- based molecules are known in the art and described in Allaway et al . (1996) , Patent Cooperation Treaty Application No. PCT/US95/08805, publication no. WO 96/02575, the content of which is incorporated by reference into this application.
- the polypeptide contains multiple units of one or more portions of a chemokine receptor.
- the polypeptide contains sequences corresponding to multiple units of one or more extracellular domains of the chemokine receptor C-C CKR-5.
- This invention also provides a pharmaceutical composition comprising effective amount of the above polypeptide and a pharmaceutically acceptable carrier.
- the term "pharmaceutically acceptable carrier” encompasses any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water, and emulsions, such as an oil/water or water/oil emulsion, and various types of wetting agents.
- This invention also provides a polypeptide having a sequence corresponding to that of a portion of an HIV-l envelope glycoprotein capable of specifically binding to the chemoreceptor C-C CKR-5.
- a sequence may be identified by routine experiments. For example, overlapping synthetic peptides representing fragments of gpl20 or gp4l can be tested in the RET assay for their ability to inhibit fusion between cells expressing the envelope glycoprotein of HIV-l clinical isolates and cells expressing CD4 and C-C CKR-5. Peptides inhibiting fusion in this assay are also screened in the RET assay for ability to inhibit fusion mediated by the envelope glycoprotein of HIV-l laboratory-adapted- strains and peptides which are inhibitory in this later assay are discarded. As an alternative method, the peptides can be tested for their ability to compete with chemokines for binding to cell expressing C-C CKR-5.
- This invention provides a pharmaceutical composition comprising effective amount of the polypeptide comprising a fragment of HIV-l glycoprotein capable of specifically binding to the chemokine receptor C-C CKR-5 and a pharmaceutically acceptable carrier.
- This invention provides an antibody or a portion of an antibody thereof capable of binding to a chemokine receptor on a CD4 + cell and inhibiting HIV-l infection of the cell.
- This invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising effective amount of antibody capable of binding to a chemokine receptor and inhibiting HIV-l infection and a pharmaceutically acceptable carrier.
- This invention provides a method of treating an HIV-l infected subject comprising administering to the subject the above pharmaceutical compositions.
- This invention provides a method of reducing the likelihood of a subject from becoming infected by HIV-l comprising administering to the subject the above pharmaceutical compositions.
- This invention provides a method for inhibiting fusion of HIV-l to CD4 + cells which comprises contacting CD4 + cells with a non-chemokine agent capable of binding to the chemokine receptor C-C CKR-5 in an amount and under conditions such that fusion of HIV-l to the CD4 + cells is inhibited.
- This invention provides a method for inhibiting HIV-l infection of CD4 + cells which comprises contacting CD4 + cells with a non-chemokine agent capable of binding to the chemokine receptor C-C CKR-5 in an amount and under conditions such that fusion of HIV-l to the CD4 + cells is inhibited, thereby inhibiting HIV-l infection.
- the non-chemokine agents of this invention are capable of binding to chemokine receptors and inhibiting fusion of HIV- 1 to CD4" cells.
- the non-chemokine agents include, but are not limited to, chemokine fragments and chemokine derivatives and analogues, but do not include naturally occurring chemokines .
- the non-chemokine agent is an oligopeptide. In another embodiment, the non-chemokine agent is a polypeptide. In still another embodiment, the non-chemokine agent is a nonpeptidyl agent.
- This invention provides a non-chemokine agent capable of binding to the chemokine receptor C-C CKR-5 and inhibiting fusion of HIV-l to CD4 + cells.
- This invention provides a molecule capable of binding to the chemokine receptor C-C CKR-5 and inhibiting fusion of HIV-l to CD4 * cells comprising a non-chemokine agent linked to a ligand capable of binding to a cell surface receptor of the CD4 + cells other than the chemokine receptor such that the binding of the non-chemokine agent to the chemokine receptor does not prevent the binding of the ligand to the other receptor.
- the cell surface receptor is CD4.
- the ligand comprises an antibody or a portion of an antibody.
- This invention provides a pharmaceutical composition comprising an amount of the above molecule effective to inhibit fusion of HIV-l to CD4* cells and a pharmaceutically acceptable carrier.
- This invention also provides a molecule capable of binding to the chemokine receptor C-C CKR-5 and inhibiting fusion of HIV-l to CD4 + cells comprising a non-chemokine agent linked to a compound capable of increasing the in vivo half-life of the non-chemokine agent.
- the compound is polyethylene glycol.
- This invention further provides a pharmaceutical composition
- a pharmaceutical composition comprising an amount of the molecule capable of binding to the chemokine receptor C-C CKR-5 and inhibiting fusion of HIV-l to CD4 + cells
- This invention provides a method for reducing the likelihood of HIV-l infection in a subject comprising administering the above pharmaceutical compositions to the subject.
- This invention provides a method for treating HIV-l infection in a subject comprising administering the above pharmaceutical compositions to the subject.
- This invention provides a method for determining whether a non-chemokine agent is capable of inhibiting the fusion of HIV-l to a CD4 ⁇ C-C CKR-5 + cell which comprises: (a) contacting a CD4 + , C-C CKR-5 * cell, which is labeled with a first dye, with a cell expressing an appropriate HIV-l envelope glycoprotein on its surface, which is labeled with a second dye, in the presence of excess of the agent under conditions permitting the fusion of the CD4" and C-C CKR-5" cell to the cell expressing the HIV-l envelope glycoprotein on its surface in the absence of an agent known to inhibit fusion of HIV-l to CD4 ⁇ C-C CKR-5 4 cell, the first and second dyes being selected so as to allow resonance energy transfer between the dyes; (b) exposing the product of step (a) to conditions which would result in resonance energy transfer if fusion has occurred; and (c) determining whether there is resonance energy transfer, the absence or reduction of transfer indicating that the agent
- the agent is an oligopeptide. In another embodiment, the agent is a polypeptide. In still another embodiment, the agent is a nonpeptidyl agent. In a further embodiment, the CD4 + cell is a PM1 cell. In a separate embodiment, the cell expressing the HIV-l envelope glycoprotein is a HeLa cell expressing HIV-1 JR . FL gpl20/gp41.
- This invention also provides a transgenic nonhuman animal which comprises an isolated DNA molecule encoding the chemokine receptor C-C CKR-5.
- this transgenic nonhuman animal further comprises an isolated DNA molecule encoding a sufficient portion of the CD4 molecule to permit binding the HIV-l envelope glycoprotein.
- This invention further provides a transgenic nonhuman animal which comprises an isolated DNA molecule encoding the chemokine receptor C-C CKR-5 and an isolated DNA molecule encoding fusin.
- this transgenic nonhuman animal further comprises an isolated DNA molecule encoding a sufficient portion of the CD4 molecule to permit binding the HIV-l envelope glycoprotein.
- One means available for producing a transgenic animal, with a mouse as an example, is as follows: Female mice are mated, and the resulting fertilized eggs are dissected out of their oviducts. The eggs are stored in an appropriate medium such as M2 medium (Hogan B. et al . Manipulating the Mouse Embryo, A Laboratory Manual, Cold Spring Harbor Laboratory (1986)) .
- DNA or cDNA encoding the C-C CKR-5 chemokine receptor or CD4 is purified from a vector by methods well known in the art .
- Inducible promoters may be fused with the coding region of the DNA to provide an experimental means to regulate expression of the trans-gene.
- tissue specific regulatory elements may be fused with the coding region to permit tissue-specific expression of the trans-gene.
- the DNA in an appropriately buffered solution, is put into a microinjection needle (which may be made from capillary tubing using a pipet puller) and the egg to be injected is put in a depression slide. The needle is inserted into the pronucleus of the egg, and the DNA solution is injected.
- the injected egg is then transferred into the oviduct of a pseudopregnant mouse (a mouse stimulated by the appropriate hormones to maintain pregnancy but which is not actually pregnant) , where it proceeds to the uterus, implants, and develops to term.
- pseudopregnant mouse a mouse stimulated by the appropriate hormones to maintain pregnancy but which is not actually pregnant
- microinjection is not the only method for inserting DNA into the egg cell, and is used here only for exemplary purposes .
- This invention provides transformed cells which comprise an isolated nucleic acid molecule encoding the chemokine receptor C-C CKR-5.
- This invention also provides an agent capable of inhibiting HIV-l infection and capable of binding to a chemokine receptor without substantially affecting the said chemokine receptor's capability to bind to chemokines.
- the term "without substantially affecting" mean that after the binding of the agent to the chemokine receptor, the chemokine receptor should still be able to bind to chemokines.
- a higher concentration of the chemokine is required to achieve the degree of binding observed if the chemokine receptor had not been bound to the agent .
- the chemokine concentration required to achieve the same binding is two fold. In another embodiment, the chemokine concentration is ten fold.
- the chemokine receptor is CCR5. In another embodiment, the chemokine receptor is CXCR4, CCR3 or CCR-2b.
- This agent may be an oligopeptide, a nonpeptidyl agent or a polypeptide.
- this agent can be an antibody or a portion of an antibody.
- This invention further provides a pharmaceutical composition comprising an amount of the above agent effective to inhibit fusion of HIV-l to CD4 + cells and a pharmaceutically acceptable carrier.
- This invention provides a method for inhibiting HIV-l infection of CD4 + cells which comprises contacting such CD4 + cells with an agent capable of inhibiting HIV-l infection and capable of binding to a chemokine receptor without substantially affecting the said chemokine receptor's capability to bind to chemokines.
- This invention also provides a molecule capable of binding to the chemokine receptor CCR5 and inhibiting fusion of HIV- 1 to CD4 + cells without substantially affecting the said chemokine receptor's capability to bind to chemokines linked to a compound capable of increasing the in vivo half-life of the non-chemokine agent.
- the compound is polyethylene glycol .
- This invention provides a pharmaceutical composition comprising an amount of the above molecule effective to inhibit HIV-l infection and a pharmaceutically acceptable carrier.
- This invention provides a method for reducing the likelihood of HIV-l infection in a subject comprising administering the above pharmaceutical composition to the subject.
- This invention provides a method for treating HIV-l infection in a subject comprising administering the above pharmaceutical composition to the subject.
- This invention provides a method for determining whether an agent is capable of inhibiting HIV-l infection comprising steps of: (a) fixing a chemokine receptor on a solid matrix;
- step (b) contacting the agent with the fixed chemokine receptor under conditions permitting the binding of the agent to the chemokine receptor; (c) removing the unbound agent; (d) contacting the fixed chemokine receptor resulting in step
- step (c) with a gpl20 in the presence of CD4 under conditions permitting the binding of the gpl20/CD4 complex and the chemokine receptor in the absence of the agent; (e) measuring the amount of bound gpl20/CD4 complex; and (f) comparing the amount determined in step (d) with the amount determined in the absence of the agent, a decrease of the amount indicating that the agent is capable of inhibiting HIV-l infection.
- This invention also provides a method for determining whether an agent is capable of inhibiting HIV-l infection comprising steps of: (a) fixing a chemokine receptor on a solid matrix; (b) contacting the agent with the fixed chemokine receptor; (c) contacting the mixture in step (b) with a gpl20 in the presence of CD4 under conditions permitting the binding of the gpl20/CD4 complex and the chemokine receptor in the absence of the agent; (d) measuring the amount of bound gpl20/CD4 complex; and (e) comparing the amount determined in step (d) with the amount determined in the absence of the agent, a decrease of the amount indicating that the agent is capable of inhibiting HIV-l infection.
- This invention also provides a method for determining whether an agent is capable of inhibiting HIV-l infection comprising steps of: (a) fixing a gpl20/CD4 complex on a solid matrix; (b) contacting the agent with the fixed gpl20/CD4 complex under conditions permitting the binding of the agent to the gpl20/CD4 complex; (c) removing unbound agent; (d) contacting the fixed gpl20/CD4 complex resulting from step (c) with a chemokine receptor under conditions permitting the binding of the gpl20/CD4 complex and the chemokine receptor in the absence of the agent; (e) measuring the amount of bound chemokine receptor; and (f) comparing the amount determined in step (e) with the amount determined in the absence of the agent, a decrease of the amount indicating that the agent is capable of inhibiting HIV-l infection.
- This invention provides a method for determining whether an agent is capable of inhibiting HIV-l infection comprising steps of: (a) fixing a gpl20/CD4 on a solid matrix; (b) contacting the agent with the fixed gpl20/CD4 complex; (c) contacting the mixture in step (b) with a chemokine receptor under conditions permitting the binding of the gpl20/CD4 complex and the chemokine receptor in the absence of the agent; (d) measuring the amount of bound chemokine receptor; (e) comparing the amount determined in step (d) with the amount determined in the absence of the agent, a decrease of the amount indicating that the agent is capable of inhibiting HIV-l infection.
- CD4 include soluble CD4, fragment of CD4 or polypeptides incorporating the gpl20 binding site of CD4 capable of binding gpl20 and enabling the binding of gpl20 to the appropriate chemokine receptor.
- gpl20 is the gpl20 from an appropriate strain of HIV-l.
- gpl20 from the macrophage tropic clinical isolate HIV-1 JR _ FL will bind to the chemokine receptor CCR5
- gpl20 from the laboratory adapted T-tropic strain HIV-1 ⁇ will bind to the chemokine receptor CXCR4.
- the CD4 is a soluble CD4.
- the chemokine receptor which may be used in the above assay includes CCR5, CXCR , CCR3 and CCR-2b.
- the chemokine receptor is expressed on a cell.
- the cell is a LI .2 cell.
- the chemokine receptor is purified and reconstituted in liposomes. Such chemokine receptor embedded in the lipid bilayer of liposomes retains the gpl20 binding activity of the receptor.
- the gpl20, CD4 or both may be labelled with a detectable marker in the above assays. Markers including radioisotope or enzymes such as horse radish peroxidase may be used in this invention.
- the gpl20 or CD4 or the chemokine receptor is labelled with biotin.
- the biotinylated gpl20, or CD4 or the chemokine receptor is detected by: (i) incubating with streptavidin-phycoerythrin, (ii) washing the incubated mixture resulting from step (i) , and (iii) measuring the amount of bound gpl20 using a plate reader, exciting at 530nm, reading emission at 590nm.
- This invention also provides an agent determined to be capable of inhibiting HIV-l infection by the above methods, which is previously unknown.
- This invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising the agent determined to be capable of inhibiting HIV-l infection by the above methods and a pharmaceutically acceptable carrier.
- the agent is an oligopeptide.
- the agent is a polypeptide.
- the agent is a nonpeptidyl agent.
- This invention also provides a molecule capable of binding to the chemokine receptor CCR5 and inhibiting fusion of HIV- 1 to CD4 + cells comprising the above determined agent linked to a compound capable of increasing the in vivo half-life of the non-chemokine agent.
- the compound is polyethylene glycol.
- This invention also provides a pharmaceutical composition comprising an amount of the above molecule effective to inhibit HIV-l infection and a pharmaceutically acceptable carrier.
- This invention provides a method for reducing the likelihood of HIV-l infection in a subject comprising administering the above pharmaceutical compositions to the subject.
- This invention provides a method for treating HIV-l infection in a subject comprising administering the above pharmaceutical composition to the subject.
- ⁇ -chemokines inhibit HIV-l replication
- NL4/3 ⁇ env which also carries the luciferase reporter gene
- envelope glycoproteins expressed in trans 10,11
- Various env-complemented viruses were tested in PM1 cells, a variant of HUT-78 that has the unique ability to support replication of primary and TCLA HIV-l strains, allowing comparison of envelope glycoprotein functions against a common cellular background (2,12) .
- MIP-l ⁇ , MIP-l ⁇ and RANTES are most active against HIV-l in combination (2,3) , and strongly inhibited infection of PM1 cells by complemented viruses whose envelopes are derived from the NSI primary strains ADA and
- PM1 cells were cultured as described by Lusso et al (12). Ficoll/hypaque- isolated PBMC from laboratory workers (LW) stimulated with PHA for 72h before depletion of CD8 + Lymphocytes with anti-CD8 immunomagne tic beads (DYNAL, Great Neck, NY) . CD4+ Lymphocytes were maintained in culture medium containing interleukin-2 (lOOU/ml; Hofmann LaRoche, Nutley, NJ) , as described previously (3).
- interleukin-2 lOOU/ml; Hofmann LaRoche, Nutley, NJ
- Target cells (l-2xlO s ) were infected with supematants (10-50ng of HIV-l p24) from 293-cells co- transfected with an NL4 / '3 Aenv- luciferase vector and a HJV-1 env -expressing vector (10,11).
- ⁇ -Chemokines (R & D Systems, Minneapolis) were added to the target cells simultaneously with virus, at the final concentrations (ng/ml) indicated in parentheses in the first column. The ⁇ -chemokine concentration range was selected based on prior studies (2,3).
- Luciferase activity in cell lysates was measured as described previously (10,11) .
- the values indicated represent luciferase activity (cpm) /ng p24/mg protein, expressed relative to that in virus-control cultures lacking ⁇ -chemokines (100%), and are the means of duplicate or sextuplicate determinations, nd, not done.
- RANTES and MIP-l ⁇ were strongly active when added individually, while other ⁇ -chemokines - MlP-l ⁇ t, MCP-1,
- the env-complementation assay was used to assess HIV-l entry into CD4+ T-cells from two control individuals (LW4 and LW5) .
- MIP-lc*, MlP-l ⁇ and RANTES strongly inhibited infection by the NSI primary strain JR-FL infection of LW4' s and LW5' s CD4 + T-cells, and weakly reduced HxB2 infection of LW cells (Table lb) , suggesting that there may be some overlap in receptor usage on activated CD4 + T-cells by different virus strains.
- BaL env-mediated replication in normal PBL was also inhibited by MlP-l ⁇ , MlP-l ⁇ and RANTES, albeit with significant inter-donor variation in sensitivity (data not shown) .
- ⁇ -chemokines inhibited HIV-l replication by showing that complete inhibition of infection of PM1 cells required the continuous presence of ⁇ -chemokines for up to 5h after addition of ADA or BaL env-complemented virus (Fig.la) .
- Pre-treatment of the cells with ⁇ -chemokines for 2h or 24h prior to infection had no inhibitory effect if the cells were subsequently washed before virus addition.
- adding ⁇ -chemokines 2h after virus only minimally affected virus entry (Fig. la) .
- a PCR-based assay was next used to detect HIV-l early DNA reverse transcripts in PM1 cells after lOh of infection; reverse transcription of ADA, but not of NL4/3, could not be detected in the presence of MIP-l ⁇ and RANTES (Fig. lb) .
- inhibition by ⁇ -chemokines requires their presence during at least one of the early stages of HIV-l replication: virus attachment, fusion and early reverse transcription. These sites of action were discriminated, first by testing whether ⁇ -chemokines inhibited binding of JR-FL or BRU gpl20 to soluble CD4, or of tetra eric CD4-IgG2 binding to HeLa-JR-FL cells expressing oligomeric envelope glycoproteins (17) .
- ⁇ -chemokines inhibit a step after CD4 binding, when conformational changes in the envelope glycoproteins lead to fusion of the viral and cellular membranes (18) .
- Cell-cell membrane fusion is also induced by the gpl20-CD4 interaction, and can be monitored directly by resonance energy transfer (RET) between fluorescent dyes incorporated into cell membranes (17) .
- RET resonance energy transfer
- HeLa-JR-FL BRU
- HeLa-BRU BRU
- MlP-l ⁇ strongly inhibited membrane fusion of HeLa-JR-FL cells with PM1 cells, whereas fusion between PM1 cells and HeLa-BRU cells was insensitive to these ⁇ -chemokines (Table 2a) .
- CD 4 * target cells mitogen-activated CD4 * lymphocytes or PM1 cells
- octadecyl rhodamine Molecular Probes, Eugene, OR
- HeLa-JR-FL cells HeLa-BRU cells (or control HeLa cells, not shown) were labeled with octadecyl fluorescein (Molecular Probes) , overnight at 37°C.
- Equal numbers of labeled target cells and env- expressing cells were mixed in 96-well plates and ⁇ -chemokines (or CD4 MAb OKT4a) were added at the final concentrations (ng/ml) indicated in parentheses in the first column. Fluorescence emission values were determined 4h after cell mixing (11) .
- RET resonance energy transfer
- %RET value is defined by a calculation described elsewhere (17) , and each is the mean of triplicate determinations. These values were, for HeLa-JR-FL and HeLa-BRU cells respectively: PM1 cells 11.5%, 10.5%; LW5
- C-C CKR-5 in HeLa-CD4 (human) , COS-CD4 (simian) and 3T3-CD4 (murine) cells rendered each of them readily infectible by the primary, NSI strains ADA and BaL in the env-complementation assay of HIV-l entry (Table 3) .
- C-C CKR-4 and C-C CKR-5 have no introns (4-8,15,22) and were isolated by PCR performed directly on a human genomic DNA pool derived from the PBMC of seven healthy donors.
- Oligonucleotides overlapping the ATG and the stop codons and containing BamHI and Xhol restriction sites for directional cloning into the pcDNA3.1 expression vector (Invitrogen
- LESTR also known as fusin or HUMSTR (4,9,24) was cloned by PCR performed directly on cDNA derived from PMl cells, using sequences derived from the NIH database. Listed below are the 5' and 3' primer pairs used in first (5-1 and 3-1) and second (5-2 and 3-2) round PCR amplification of the CKR genes directly from human genomic DNA, and of LESTR from PMl cDNA. Only a single set of primers was used to amplify CKR-5.
- L/5-1 AAG CTT GGA GAA CCA GCG GTT ACC ATG GAG GGG
- ATC (SEQ ID NO: 9) ;
- L/5-2 GTC TGA GTC TGA GTC AAG CTT GGA GAA CCA (SEQ ID NO: 10) ;
- L/3-1 CTC GAG CAT CTG TGT TAG CTG GAG TGA AAA CTT GAA GAC
- CKR-l:Cl/5-l AAG CTT CAG AGA GAA GCC GGG ATG GAA ACT CC
- Cl/3-1 CTC GAG CTG AGT CAG AAC CCA GCA GAG AGT TC (SEQ ID NO: 15);
- CKR-2a:C2/5-l AAG CTT CAG TAC ATC CAC AAC ATG CTG TCC AC (SEQ ID NO: 17) ;
- C2/5-2 GTC TGA GTC TGA GTC AAG CTT CAG TAC ATC (SEQ ID NO:
- C2/3-1 CTC GAG CCT CGT TTT ATA AAC CAG CCG AGA C (SEQ ID NO:
- C2/3-2 GTC TGA GTC TGA GTC CTC GAG CCT CGT TTT (SEQ ID NO: 19);
- C3/3-1 CTC GAG CAG ACC TAA AAC ACA ATA GAG AGT TCC (SEQ ID NO: 1
- CKR -4: C4/5-1 AAG CTT CTG TAG AGT TAA AAA ATG AAC CCC ACG
- C4/3-1 CTC GAG CCA TTT CAT TTT TCT ACA GGA CAG CAT C (SEQ ID NO: 27) ;
- CKR- 5: C5/5-12 GTC TGA GTC TGA GTC AAG CTT AAC AAG ATG GAT
- TAT CAA (SEQ ID NO: 29) ;
- C5/3-12 GTC TGA GTC TGA GTC CTC GAG TCC GTG TCA CAA GCC
- CAC (SEQ ID NO: 30) .
- the human CD4 -expressing cell lines HeLa-CD4 (P42) , 3T3-CD4 (sc6) and COS-CD4 (Z28T1) (23) were transfected with the different pcDNA3.1-CKR constructs by the calcium phosphate method, then infected 48h later with different reporter viruses (200ng of HIV-l p24/10 6 cells) in the presence or absence of ⁇ -chemokines (400ng/ml each of RANTES, MlP-lot and MlP-l ⁇ ) . Luciferase activity in cell lysates was measured 48h later (10,11) .
- ⁇ -Chemokine blocking data is only shown for C-C CKR-5, as infection mediated by the other C-C CKR genes was too weak for inhibi tion to be quantifiable .
- PCR-based assays of HIV- l entry a low level of entry of NL4/3 and ADA into C-C CKR-1 expressing cells (da ta not shown) was consis ten tly observed.
- C-C CKR-5 The second receptor function of C-C CKR-5 was confirmed in assays of env-mediated membrane fusion.
- C-C CKR-5 was transiently expressed in COS and HeLa cell lines that permanently expressed human CD4 , both cell lines fused strongly with HeLa cells expressing the JR-FL envelope glycoproteins, whereas no fusion occurred when control plasmids were used (data not shown) .
- Expression of LESTR instead of C-C CKR-5 did not permit either C0S-CD4 or HeLa- CD4 cells to fuse with HeLa-JR-FL cells, but did allow fusion between C0S-CD4 cells and HeLa-BRU cells (data not shown) .
- the fusion capacity of ⁇ -chemokine receptors was also tested in the RET assay.
- the extent of fusion between HeLa-JR-FL cells and C-C CKR-5-expressing HeLa-CD4 cells was greater than the constitutive level of fusion between HeLa-BRU cells and HeLa-CD4 cells (Fig.2) .
- the fusion-conferring function of C-C CKR-5 for primary, NSI HIV-l strains has therefore been confirmed in two independent fusion assays.
- MlP-l ⁇ , MIP-l ⁇ and RANTES inhibit HIV-l infection at the entry stage, by interfering with the virus-cell fusion reaction subsequent to CD4 binding. It was also shown that C-C CKR-5 can serve as a second receptor for entry of primary NSI strains of HIV-l into CD4+ T-cells, and that the interaction of ⁇ -chemokines with C-C CKR-5 inhibits the HIV-l fusion reaction.
- Recombinant gp41 (IIIB) ectodomain was from Viral Therapeutics Inc., and V3 peptides were obtained either from Repligen or the UK MRC AIDS Reagent Repository.
- Recombinant MN gpl20 (Genentech) , SF-2 gpl20 (Chiron) and CM243 gpl20 were provided by the NIAID AIDS Reagents Repository, and W61D gpl20 (SmithKline Beecham, Belgium) was from the UK MRC AIDS Reagent Repository.
- the expression of the gene is under the control of the cytomegalovirus immediate-early promoter.
- the V3 loops were excised by the splicing-by-overlap- extension technique, such that the cysteines defining the loop were retained and spanned by the peptide sequence TGAGH. All constructs were sequenced to verify that no mutations were introduced during the cloning manipulations.
- the proteins were expressed in stably transfected Chinese hamster ovary cells (DXB-11) , selected in nucleoside-free medium and amplified using methotrexate, following previously described methods (17) .
- the secreted proteins were purified to >95% homogeneity in a non-denaturing process comprising an ion exchange, Galanthus nivalus lectin affinity and gel filtration chromatography.
- the purified proteins bound sCD4 with nanomolar affinity(18) .
- SF162 gpl60 For expression of SF162 gpl60, a 3.5-kb EcoRl-BamHl fragment containing the env gene was excised from the SV40-based vector pSM and subcloned into the Rl/Bgllll sites of the ⁇ - actin-based expression vector pCAGGS.
- SF170 gpl60 For expression of SF170 gpl60, a 3.8-kb fragment containing the env gene was excised from the pBSKS* plasmid, blunted by treatment with T4 DNA polymerase, and subcloned into the RV/Xhol sites of pCAGGS.
- the expression plasmids were transfected into 293 T cells by calcium phosphate co-precipitation. Soluble gpl20 in the culture supernatant was collected after three days, filtered through 0.2- ⁇ m filters and concentrated over an Amicon 1000 membrane.
- the preparation of soluble, oligomeric forms of the JR-FL and 94RW020 envelope glycoproteins (and also monomeric gpl20 from 92TH014) was as follows.
- the JR-FL env gene was provided by I. Chen (UCLA) and the env genes of 92TH014 and 92RW020 were obtained from the NIAID AIDS Reagent Repository(30) .
- the monomeric gpl20 or oligomeric gpl20/gp41 concentrations in unpurified culture supematants were estimated by denaturing the proteins (19) , then dot- blotting onto nitrocellulose membranes and detecting the gpl20 with a cocktail of murine monoclonal antibodies to continuous epitopes (19) , followed by an anti-mouse IgG-HRP conjugate and the ECL chemiluminescence system (Amersham) .
- Purified, monomeric JR-FL gpl20 was used as a concentration standard(17) .
- the concentration of oligomeric gpl20/gp41 complexes was defined as the total concentration of monomeric gpl20 subunits in the preparation.
- High-affinity CD4 binding of the gpl20s was confirmed by enzyme-linked immunosorbent assay (ELISA) (19) .
- PBMCs peripheral blood mononuclear cells
- PBMCs peripheral blood mononuclear cells
- CD4 T cells were purified from the activated PBMCs by positive selection using anti-CD4 immunomagnetic beads (Dynal Inc.) .
- the purified lymphocytes were cultured for at least 3 days at 2 x 10 6 / ml in medium containing IL- 2 (200 U ml "1 ) before being used in the 125 I-MIP-10 binding assay.
- the cells were screened for CCR-5-defective alleles (14) , and only cells from wild-type donors were used (except when specified) .
- 293 cells were transfected with pcDNA3.
- l-ckr-5 (ref. 1) using the calcium phosphate method, and resistant clones were selected in culture medium containing 1 ⁇ g ml "1 neomycin (G418; Sigma) . Resistant cells were subcloned and tested for CCR-5 expression in a binding assay using 125 I-MIP-l( ⁇ .
- T cells were washed twice in ice-cold binding buffer (RPMI).
- the / S-chemokine receptor CCR-5 is an essential co-factor for fusion of HIV-l strains of the non-syncytium-inducing (NSI) phenotype with CD4 + T-cells (1-5) .
- the primary binding site for human immunodeficiency virus (HIV) -1 is the CD4 molecule, and the interaction is mediated by the viral surface glycoprotein gpl20 (6, 7) .
- the mechanism of CCR-5 function during HIV-l entry has not been defined, but we have shown previously that its / ⁇ -chemokine ligands prevent HIV-l from fusing with the cell(l) .
- CCR-5 acts as a second binding site for HIV-l simultaneously with or subsequent to the interaction between gpl20 and CD4.
- CD4 binding although not absolutely necessary for the gpl20-CCR-5 interaction, greatly increases its efficiency.
- MIP-ljS is the most specific ligand for CCR-5 (8-10) because MIP-lcf and RANTES also bind with high affinity to other members of the ⁇ -chemokine receptor family on lymphoid cells (8-11) .
- MIP-10 as the CCR-5 ligand in the competition assays.
- CCR-5 is a mitogen-response gene. Its expression in quiescent, purified CD4" T-cells is usually minimal, but 3 days after activation of the cells by phytohaemagglutinin and interleukin (IL)-2, we observed strong increases in CCR-5 messenger RNA and 15 I-labelled-
- CD4 + T cells from individuals homozygous for defective CCR-5 alleles (13 , 14) .
- the amount of specific (that is, cold MIP-1/3-competed) 125 I-MIP-l ⁇ (0.1 nM) binding to cells from three such individuals was 92 ⁇ 12 c.p.m. per 2 x 10 6 cells (mean + s.d.) .
- mean binding to cells from 21 control individuals was 1,044 + 1,073 c.p.m. per 2 x 10 G cells (range, 222-4,846 c.p.m.) .
- Most of the 125 I-MIP-1 / S reactivity with activated CD4 + T cells therefore derives from binding to CCR-5.
- Recombinant proteins were titrated in the presence of 0.1 nM 125 I-MIP-lj8 and added to activated CD4 + T cells. Percentage inhibitions of 125 I-MIP-l ⁇ binding at each gpl20 concentration are shown, and are the means ⁇ s.d. of 2-4 independent experiments. No value indicates that the gpl20 molecule was not tested at that concentration (several molecules were not available at concentrations > lug ml "1 ) . * An oligomeric gpl20/gp41 complex.
- peptides (15-residue if not specified) from the V3 loops of the following strains were also inactive: JR-FL (32-residue) , RA, VS, Case-B (each NSI) ; HxB2, MN, SF- 2 (each TCLA) (peptides were added at l ⁇ g ml "1 , the approximate molar equivalent of 60 ⁇ g ml "1 gpl20) .
- HIV-l strains from genetic subtypes A, B, C and E can use CCR-5 for entry(3) , and we have found that MlP-l ⁇ inhibits the replication of most primary, NSI HIV-l strains from subtypes A to E. This breadth of reactivity of HIV-l with CCR-5 extend to the 125 I-MIP-1
- JR-FL (subtype B) , SF162 (B) , 61D (B) , 92TH014 (B) , SF170
- JR-FL gpl20 (2ug ml "1 ) inhibition of 125 I-MIP-l3 binding to activated CD4 + T cells was tested in the presence or absence of sCD4 (50 ⁇ g ml "1 ) or monoclonal antibodies to CD4 (50 ⁇ g ml "1 ) or antibodies to gpl20 (20 ⁇ g ml "1 ) .
- Mean percentage reversals of the competitive effect of gpl20 in the presence of each antibody are shown.
- Anti-gpl20 monoclonal antibodies (or sCD4) able to neutralize HIV-1 JR . FL
- JR-FL gpl20 and CCR-5 requires at least 100-fold higher gpl20 concentrations on CD4 " cells than on CD4 * cells.
- binding of gpl20 to CD4 on the cell surface increases the probability of a gpl20-CCR-5 interaction; either a gpl20-CD4-CCR-5 ternary complex forms, or there are sequential interactions of gpl20 with CD , then CCR-5.
- One possibility is that the high-affinity association of gpl20 with CD4 increases the probability of a lower-affinity interaction of gpl20 with
- CCR-5 (a proximity effect) .
- sCD4 does not substitute for cell-surface CD4, at least with JR-FL gpl20.
- binding to CD4 may be necessary to (better) expose a CCR-5 binding site on gpl20. This may be especially important in the context of virions, where some regions of the oligomeric envelope glycoproteins (including the V3 loop) that are accessible on monomeric gpl20 are not optimally exposed before CD4 binding (18) .
- the monoclonal antibodies 2G12, 17b, 447-D, 48d, IgGlbl2, G3-508 and 697-D were also tested against the oligomeric JR-FL gpl20/gp41 protein, and all except 697-D inhibited the interaction of this protein with CCR-5 (not shown) .
- simian immunodeficiency virus (SIV) strains can also use human CCR- 5 as a second receptor (Z.W. Chen and P. Marx, personal communication) , but the V3 regions of HIV-l and SIV have almost no primary sequence homology. Can all these sequences each form a binding site for the same, conserved cellular protein, when similar V3 sequences from TCLA HIV-l strains cannot (Table 4)? Twin-site models of the interaction of ligands with chemokine receptors (8) leave open the possibility that a relatively conserved section of the V3 loop could be one component of a multi-point binding site for CCR-5 on gpl20.
- the CCR-5 binding site must include a region of gpl20 that is strongly conserved across the primate immunodeficiency viruses, not just across the HIV-l genetic subtypes. Whether this is also the case for HIV-l interactions with CXCR-4 remains to be determined.
- the structure of the V3 loop may influence the nature of a complex binding site for CCR-5 on gpl20.
- a region of gpl20 overlapped by (but not necessarily identical to) the CD4- induced epitopes of monoclonal antibodies 48d and 17b is a good candidate for such a site.
- These antibodies recognize similar conformationally sensitive structures that are probably located around the bases of the VI, V2 and V3 loops (22,23) .
- V3 loop from both HxBc2 gpl20 and JR-FL gpl20 destroys the 48d and 17b epitopes (22, 23) (unpublished data) , which may be relevant to the inability of the ⁇ -V3 JR-FL gpl20 to interact with CCR-5 (Fig. 5A) , and single amino-acid changes in the V3 and C4 regions of HIV-I LA! also have major effects on the structure of these epitopes (24) .
- sCD4 inhibited the interaction between JR-FL gpl20 and CCR-5 on CD4 * cells, for some strains of HIV-l and (especially) HIV-2 and SIV, sCD4 might enhance the efficiency of second- receptor interactions, and thereby facilitate the entry of these primate immunodeficiency viruses into CD4 or CD4* cells (25, 26.) .
- This assay has been adapted for drug screening purposes to a 96-well microplate format where binding of the sCD4/gpl20 complexes to CCR5 + /CD4 " cells is measured using a fluorometric plate reader.
- One method is as follows:
- Synthetic peptides representing the four extracellular domains of human CCR5 were made by Quality Controlled Biochemicals (Hopkinton, MA) and tested for ability to inhibit membrane fusion mediated by the envelope glycoproteins of the LAI or JR-FL strains of HIV-l using the resonance energy transfer (RET) assay described above. Specific inhibition of fusion mediated by the JR-FL envelope glycoprotein was seen using the ECL2 peptide but not other peptides. ECL2 inhibited fusion between HeLa-env JR . FL cells and PMl cells by 97% at 100 ⁇ g/ml, 65% at 33 ⁇ g/ml and 15% at 11 ⁇ g/ml (mean of two assays) .
- the bicyclam JM3100 obtained from Dr. J. Moore (Aaron Diamond AIDS Research Center, NY) was tested for ability to inhibit membrane fusion mediated by the envelope glycoproteins of the LAI or JR-FL strains of HIV-l using the resonance energy transfer (RET) assay described above. As illustrated in Fig. 6, this molecule specifically and potently inhibits fusion mediated by gpl20/gp41 from the HIV-lu strain, and not from the HIV-l ⁇ . ⁇ strain. These data suggest that this molecule specifically inhibits HIV fusion by blocking the interaction between HIV-1 ⁇ gpl20 and CXCR4. SEQUENCE LISTING
- MOLECULE TYPE DNA (genomic)
- MOLECULE TYPE DNA (genomic)
- MOLECULE TYPE DNA (genomic)
- MOLECULE TYPE DNA (genomic)
- MOLECULE TYPE DNA (genomic)
- MOLECULE TYPE DNA (genomic)
- MOLECULE TYPE DNA (genomic)
- MOLECULE TYPE DNA (genomic)
- xi SEQUENCE DESCRIPTION: SEQ ID NO: 12: GTCTGAGTCT GAGTCCTCGA GCATCTGTGT 30
- MOLECULE TYPE DNA (genomic)
- SEQUENCE DESCRIPTION SEQ ID NO:13: AAGCTTCAGA GAGAAGCCGG GATGGAAACT CC 32
- MOLECULE TYPE DNA (genomic)
- MOLECULE TYPE DNA (genomic)
- MOLECULE TYPE DNA (genomic)
- MOLECULE TYPE DNA (genomic)
- MOLECULE TYPE DNA (genomic)
- MOLECULE TYPE DNA (genomic)
- MOLECULE TYPE DNA (genomic)
- xi SEQUENCE DESCRIPTION: SEQ ID NO:21: AAGCTTCAGG GAGAAGTGAA ATGACAACC 29
- MOLECULE TYPE DNA (genomic)
- MOLECULE TYPE DNA (genomic)
- MOLECULE TYPE DNA (genomic)
- MOLECULE TYPE DNA (genomic)
- SEQUENCE DESCRIPTION SEQ ID NO:25: AAGCTTCTGT AGAGTTAAAA AATGAACCCC ACGG 34
- MOLECULE TYPE DNA (genomic)
- MOLECULE TYPE DNA (genomic)
- MOLECULE TYPE DNA (genomic)
- MOLECULE TYPE DNA (genomic)
- MOLECULE TYPE DNA (genomic)
- xi SEQUENCE DESCRIPTION: SEQ ID NO:30: GTCTGAGTCT GAGTCCTCGA GTCCGTGTCG CAAGCCCAC 39
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- AIDS & HIV (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
La présente invention concerne un polypeptide comprenant un fragment d'un récepteur de chémokines capable d'inhiber l'infection à VIH-1. Dans une forme d'exécution, le récepteur de chémokines est C-C CKR-5 et dans une autre forme d'execution, le fragment comprend au moins un domaine extracellulaire du récepteur de chémokines C-C CKR-5. La présente invention concerne en outre différentes uitlisations du récepteur de chémokines destinées à inhiber l'infection à VIH-1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU33902/97A AU3390297A (en) | 1996-06-14 | 1997-06-13 | Uses of a chemokine receptor for inhibiting hiv-1 infection |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1994196P | 1996-06-14 | 1996-06-14 | |
US66509096A | 1996-06-14 | 1996-06-14 | |
US08/665,090 | 1996-06-14 | ||
US60/019,941 | 1996-06-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997047318A1 true WO1997047318A1 (fr) | 1997-12-18 |
Family
ID=26692788
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/010619 WO1997047319A1 (fr) | 1996-06-14 | 1997-06-13 | Utilisations d'un recepteur de la chemokine dans l'inhibition de l'infection par le vih-1 |
PCT/US1997/010233 WO1997047318A1 (fr) | 1996-06-14 | 1997-06-13 | Utilisations d'un recepteur de chemokines en vue de l'inhibition de l'infection a vih-1 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/010619 WO1997047319A1 (fr) | 1996-06-14 | 1997-06-13 | Utilisations d'un recepteur de la chemokine dans l'inhibition de l'infection par le vih-1 |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0956044A4 (fr) |
JP (1) | JP4183754B2 (fr) |
AU (2) | AU3390297A (fr) |
CA (1) | CA2257991A1 (fr) |
WO (2) | WO1997047319A1 (fr) |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000029556A2 (fr) * | 1998-11-17 | 2000-05-25 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Identification des glycosphingolipides qui favorisent la penetration du vih-1 dans les cellules |
EP1009435A1 (fr) * | 1997-06-13 | 2000-06-21 | Progenics Pharmaceuticals, Inc. | Prevention de l'infection des cellules cd4?+ par le hiv-1 |
WO2000040964A1 (fr) * | 1999-01-08 | 2000-07-13 | The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health | Inhibition de l'interaction entre cd4 et ccr5 |
WO2000055207A1 (fr) * | 1999-03-16 | 2000-09-21 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services, The National Institutes Of Health | Nouvelle proteine chimere permettant de prevenir et de traiter l'infection due au vih |
WO2001016182A2 (fr) * | 1999-08-27 | 2001-03-08 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Polypeptides de liaison a la glycoproteine gp120 du virus de l'immunodeficience humaine (vih), acides nucleiques, anticorps et compositions associes, et methodes d'utilisation |
WO2001030809A1 (fr) * | 1999-10-28 | 2001-05-03 | Nissui Pharmaceutical Co., Ltd. | Peptides cycliques et vaccins contre le sida |
WO2001042308A2 (fr) * | 1999-12-08 | 2001-06-14 | Novartis Ag | Methodes et compositions utiles pour l'inhibition de l'infection, dependante de ccr5, de cellules par vhi-1 |
US6265184B1 (en) | 1995-12-20 | 2001-07-24 | Icos Corporation | Polynucleotides encoding chemokine receptor 88C |
EP1144006A2 (fr) * | 1998-12-16 | 2001-10-17 | Progenics Pharmaceuticals, Inc. | Inhibition synergique de la fusion et la liaison du vih-1 et composition et anticorps s'y rapportant |
US6399078B1 (en) | 1998-06-01 | 2002-06-04 | University Of Maryland Biotechnology Institute | Chemokine—glycosaminoglycan complexes and their use in treating or preventing receptor mediated diseases |
US6511826B2 (en) | 1995-06-06 | 2003-01-28 | Human Genome Sciences, Inc. | Polynucleotides encoding human G-protein chemokine receptor (CCR5) HDGNR10 |
US6743594B1 (en) | 1995-06-06 | 2004-06-01 | Human Genome Sciences, Inc. | Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5) |
US7115262B1 (en) | 1999-03-16 | 2006-10-03 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric protein for prevention and treatment of HIV infection |
US7122185B2 (en) | 2002-02-22 | 2006-10-17 | Progenics Pharmaceuticals, Inc. | Anti-CCR5 antibody |
US7151087B2 (en) | 1996-05-28 | 2006-12-19 | The United States Of America As Represented By The Department Of Health And Human Resources | CC chemokine receptor 5 DNA, new animal models and therapeutic agents for HIV infection |
US7175988B2 (en) | 2001-02-09 | 2007-02-13 | Human Genome Sciences, Inc. | Human G-protein Chemokine Receptor (CCR5) HDGNR10 |
US7304127B2 (en) | 1999-08-27 | 2007-12-04 | United States Of America As Represented By The Secretary, Department Of Health And Human Services | Polypeptides that bind HIV gp120 and related nucleic acids, antibodies, compositions, and methods of use |
US7393934B2 (en) | 2001-12-21 | 2008-07-01 | Human Genome Sciences, Inc. | Human G-protein chemokine receptor (CCR5) HDGNR10 |
EP1900376A3 (fr) * | 1998-12-16 | 2008-10-15 | Progenics Pharmaceuticals, Inc. | Inhibition synergique de la fusion et la fixation de l'HIV-1 sur des compositions et anticorps |
US7501123B2 (en) | 2004-03-12 | 2009-03-10 | Human Genome Sciences, Inc. | Human G-protein chemokine receptor (CCR5) HDGNR10 |
US7935797B2 (en) | 1996-04-01 | 2011-05-03 | Progenics Pharmaceuticals Inc. | CCR5 chemokine receptor-specific monoclonal antibodies capable of inhibiting HIV-1 cell fusion |
US8821877B2 (en) | 2005-07-22 | 2014-09-02 | Cytodyn Inc. | Methods for inhibiting HIV-1 replication involving the administration of an anti-CCR5 receptor monoclonal antibody and small molecule CCR5 receptor antagonist |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0847452B1 (fr) | 1995-06-07 | 2009-04-01 | Progenics Pharmaceuticals, Inc. | Anticorps monoclonal destiné à inhiber la fusion membranaire médiée par la glycoprotéine d'enveloppe de vih-1 |
US7118859B2 (en) | 1996-01-17 | 2006-10-10 | Progenics Pharmaceuticals, Inc. | Methods for inhibiting HIV-1 infection |
US6528625B1 (en) | 1996-10-28 | 2003-03-04 | Millennium Pharmaceuticals, Inc. | Anti-CCR5 antibodies and kits comprising same |
US6153431A (en) * | 1997-05-30 | 2000-11-28 | Fond Mondiale Rech & Prev Sida | Human immunodeficiency virus co-receptor variants associated with resistance to virus infection |
US6312689B1 (en) | 1998-07-23 | 2001-11-06 | Millennium Pharmaceuticals, Inc. | Anti-CCR2 antibodies and methods of use therefor |
US6696550B2 (en) | 1998-07-23 | 2004-02-24 | Millennium Pharmaceuticals, Inc. | Humanized anti-CCR2 antibodies and methods of use therefor |
US6727349B1 (en) | 1998-07-23 | 2004-04-27 | Millennium Pharmaceuticals, Inc. | Recombinant anti-CCR2 antibodies and methods of use therefor |
JP2000229997A (ja) | 1999-02-10 | 2000-08-22 | Nissui Pharm Co Ltd | 環状ペプチド及びエイズワクチン |
GB9930443D0 (en) | 1999-12-22 | 2000-02-16 | King S College London | Novel use of heat shock proteins |
US7138119B2 (en) | 2000-09-15 | 2006-11-21 | Progenics Pharmaceuticals, Inc. | Compositions and methods for inhibition of HIV-1 infection |
US7060273B2 (en) | 2001-04-06 | 2006-06-13 | Progenics Pharmaceuticals, Inc. | Methods for inhibiting HIV-1 infection |
ES2524803T3 (es) | 2002-12-19 | 2014-12-12 | The Scripps Research Institute | Composiciones y métodos para estabilizar la transtiretina e inhibir el plegamiento anómalo de la transtiretina |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5126433A (en) * | 1986-08-21 | 1992-06-30 | The Trustees Of Columbia University In The City Of New York | Soluble forms of the t cell surface protein cd4 |
US5869624A (en) * | 1993-03-26 | 1999-02-09 | Progenics Pharmaceuticals, Inc. | HIV-1 vaccines, antibody compositions related thereto, and therapeutic and prophylactic uses thereof |
EP0738330A4 (fr) * | 1993-12-17 | 2002-10-30 | Progenics Pharm Inc | Procedes d'utilisation d'un dosage, fonde sur le transfert d'energie de resonnance, concernant la fusion d'une membrane a mediation par glycoproteine d'enveloppe de vih-1, et trousse pour la mise en uvre de ces procedes |
WO1996039437A1 (fr) * | 1995-06-06 | 1996-12-12 | Human Genome Sciences, Inc. | Chemokine recepteur hdgnr10 aux proteines g humaines |
EP0847452B1 (fr) * | 1995-06-07 | 2009-04-01 | Progenics Pharmaceuticals, Inc. | Anticorps monoclonal destiné à inhiber la fusion membranaire médiée par la glycoprotéine d'enveloppe de vih-1 |
DK1482042T3 (da) * | 1996-03-01 | 2009-06-15 | Euroscreen Sa | Aktive og inaktive CC-kemokinreceptorer og nukleinsyremolekyler der koder for receptoren |
-
1997
- 1997-06-13 WO PCT/US1997/010619 patent/WO1997047319A1/fr active Application Filing
- 1997-06-13 JP JP50189598A patent/JP4183754B2/ja not_active Expired - Fee Related
- 1997-06-13 AU AU33902/97A patent/AU3390297A/en not_active Abandoned
- 1997-06-13 AU AU34026/97A patent/AU735460B2/en not_active Ceased
- 1997-06-13 WO PCT/US1997/010233 patent/WO1997047318A1/fr active Application Filing
- 1997-06-13 EP EP97930120A patent/EP0956044A4/fr not_active Withdrawn
- 1997-06-13 CA CA002257991A patent/CA2257991A1/fr not_active Abandoned
Non-Patent Citations (13)
Cited By (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6511826B2 (en) | 1995-06-06 | 2003-01-28 | Human Genome Sciences, Inc. | Polynucleotides encoding human G-protein chemokine receptor (CCR5) HDGNR10 |
US7160546B2 (en) | 1995-06-06 | 2007-01-09 | Human Genome Sciences, Inc. | Human G-protein chemokine receptor (CCR5) HDGNR10 |
US6800729B2 (en) | 1995-06-06 | 2004-10-05 | Human Genome Sciences, Inc. | Human G-Protein chemokine receptor HDGNR10 (CCR5 receptor) |
US6759519B2 (en) | 1995-06-06 | 2004-07-06 | Human Genome Sciences, Inc. | Antibodies to human G-protein chemokine receptor HDGNR10 (CCR5receptor) |
US6743594B1 (en) | 1995-06-06 | 2004-06-01 | Human Genome Sciences, Inc. | Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5) |
US7662548B2 (en) | 1995-12-20 | 2010-02-16 | Euroscreen S.A. ICOS Corporation | Method of screening for modulators of HIV infection |
US6797811B1 (en) | 1995-12-20 | 2004-09-28 | Icos Corporation | Antibodies to chemokine receptor 88C |
US6265184B1 (en) | 1995-12-20 | 2001-07-24 | Icos Corporation | Polynucleotides encoding chemokine receptor 88C |
US6268477B1 (en) | 1995-12-20 | 2001-07-31 | Icos Corporation | Chemokine receptor 88-C |
US7935797B2 (en) | 1996-04-01 | 2011-05-03 | Progenics Pharmaceuticals Inc. | CCR5 chemokine receptor-specific monoclonal antibodies capable of inhibiting HIV-1 cell fusion |
US7374872B2 (en) | 1996-05-28 | 2008-05-20 | The United States Of America As Represented By The Department Of Health And Human Services | CC chemokine receptor 5 DNA, new animal models and therapeutic agents for HIV infection |
US8198042B2 (en) | 1996-05-28 | 2012-06-12 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | CC chemokine receptor 5 DNA, new animal models and therapeutic agents for HIV infection |
US7151087B2 (en) | 1996-05-28 | 2006-12-19 | The United States Of America As Represented By The Department Of Health And Human Resources | CC chemokine receptor 5 DNA, new animal models and therapeutic agents for HIV infection |
EP1009435A4 (fr) * | 1997-06-13 | 2003-04-09 | Progenics Pharm Inc | Prevention de l'infection des cellules cd4?+ par le hiv-1 |
EP1009435A1 (fr) * | 1997-06-13 | 2000-06-21 | Progenics Pharmaceuticals, Inc. | Prevention de l'infection des cellules cd4?+ par le hiv-1 |
US6399078B1 (en) | 1998-06-01 | 2002-06-04 | University Of Maryland Biotechnology Institute | Chemokine—glycosaminoglycan complexes and their use in treating or preventing receptor mediated diseases |
WO2000029556A3 (fr) * | 1998-11-17 | 2000-11-23 | Us Health | Identification des glycosphingolipides qui favorisent la penetration du vih-1 dans les cellules |
WO2000029556A2 (fr) * | 1998-11-17 | 2000-05-25 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Identification des glycosphingolipides qui favorisent la penetration du vih-1 dans les cellules |
EP1144006A4 (fr) * | 1998-12-16 | 2004-11-24 | Progenics Pharm Inc | Inhibition synergique de la fusion et la liaison du vih-1 et composition et anticorps s'y rapportant |
EP1900376A3 (fr) * | 1998-12-16 | 2008-10-15 | Progenics Pharmaceuticals, Inc. | Inhibition synergique de la fusion et la fixation de l'HIV-1 sur des compositions et anticorps |
EP1144006A2 (fr) * | 1998-12-16 | 2001-10-17 | Progenics Pharmaceuticals, Inc. | Inhibition synergique de la fusion et la liaison du vih-1 et composition et anticorps s'y rapportant |
WO2000040964A1 (fr) * | 1999-01-08 | 2000-07-13 | The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health | Inhibition de l'interaction entre cd4 et ccr5 |
JP2002538814A (ja) * | 1999-03-16 | 2002-11-19 | ザ ガバメント オブ ザ ユナイテッドステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ ザ ナショナル インステ | Hiv感染の予防および治療のための新規キメラタンパク質 |
US7115262B1 (en) | 1999-03-16 | 2006-10-03 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric protein for prevention and treatment of HIV infection |
AU765218B2 (en) * | 1999-03-16 | 2003-09-11 | Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The | A novel chimeric protein for prevention and treatment of HIV infection |
WO2000055207A1 (fr) * | 1999-03-16 | 2000-09-21 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services, The National Institutes Of Health | Nouvelle proteine chimere permettant de prevenir et de traiter l'infection due au vih |
US8420099B2 (en) | 1999-03-16 | 2013-04-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Chimeric protein for prevention and treatment of HIV infection |
WO2001016182A3 (fr) * | 1999-08-27 | 2002-08-15 | Us Health | Polypeptides de liaison a la glycoproteine gp120 du virus de l'immunodeficience humaine (vih), acides nucleiques, anticorps et compositions associes, et methodes d'utilisation |
US7304127B2 (en) | 1999-08-27 | 2007-12-04 | United States Of America As Represented By The Secretary, Department Of Health And Human Services | Polypeptides that bind HIV gp120 and related nucleic acids, antibodies, compositions, and methods of use |
WO2001016182A2 (fr) * | 1999-08-27 | 2001-03-08 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Polypeptides de liaison a la glycoproteine gp120 du virus de l'immunodeficience humaine (vih), acides nucleiques, anticorps et compositions associes, et methodes d'utilisation |
US6943233B1 (en) | 1999-10-28 | 2005-09-13 | Nissui Pharmaceutical Co., Ltd. | Cyclic peptides and aids vaccines |
WO2001030809A1 (fr) * | 1999-10-28 | 2001-05-03 | Nissui Pharmaceutical Co., Ltd. | Peptides cycliques et vaccins contre le sida |
WO2001042308A2 (fr) * | 1999-12-08 | 2001-06-14 | Novartis Ag | Methodes et compositions utiles pour l'inhibition de l'infection, dependante de ccr5, de cellules par vhi-1 |
WO2001042308A3 (fr) * | 1999-12-08 | 2002-05-02 | Novartis Ag | Methodes et compositions utiles pour l'inhibition de l'infection, dependante de ccr5, de cellules par vhi-1 |
US7862818B2 (en) | 2001-02-09 | 2011-01-04 | Human Genome Sciences, Inc. | Method of inhibiting human G-protein chemokine receptor (CCR5) HDGNR10 |
US7175988B2 (en) | 2001-02-09 | 2007-02-13 | Human Genome Sciences, Inc. | Human G-protein Chemokine Receptor (CCR5) HDGNR10 |
US7393934B2 (en) | 2001-12-21 | 2008-07-01 | Human Genome Sciences, Inc. | Human G-protein chemokine receptor (CCR5) HDGNR10 |
US7122185B2 (en) | 2002-02-22 | 2006-10-17 | Progenics Pharmaceuticals, Inc. | Anti-CCR5 antibody |
US7501123B2 (en) | 2004-03-12 | 2009-03-10 | Human Genome Sciences, Inc. | Human G-protein chemokine receptor (CCR5) HDGNR10 |
US8821877B2 (en) | 2005-07-22 | 2014-09-02 | Cytodyn Inc. | Methods for inhibiting HIV-1 replication involving the administration of an anti-CCR5 receptor monoclonal antibody and small molecule CCR5 receptor antagonist |
Also Published As
Publication number | Publication date |
---|---|
CA2257991A1 (fr) | 1997-12-18 |
EP0956044A4 (fr) | 2005-01-05 |
JP2001503608A (ja) | 2001-03-21 |
JP4183754B2 (ja) | 2008-11-19 |
AU3402697A (en) | 1998-01-07 |
WO1997047319A1 (fr) | 1997-12-18 |
AU735460B2 (en) | 2001-07-12 |
AU3390297A (en) | 1998-01-07 |
EP0956044A1 (fr) | 1999-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU735460B2 (en) | Uses of a chemokine receptor for inhibiting HIV-1 infection | |
US20060194244A1 (en) | Uses of a chemokine receptor for inhibiting HIV-1 infection | |
US6344545B1 (en) | Method for preventing HIV-1 infection of CD4+ cells | |
Broder et al. | Chemokine receptors and HIV | |
AU753362B2 (en) | Method for preventing HIV-1 infection of CD4+ cells | |
Dragic et al. | HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5 | |
US8198042B2 (en) | CC chemokine receptor 5 DNA, new animal models and therapeutic agents for HIV infection | |
AU728512B2 (en) | Method for preventing HIV-1 infection of CD4+ cells | |
US7935797B2 (en) | CCR5 chemokine receptor-specific monoclonal antibodies capable of inhibiting HIV-1 cell fusion | |
KR100462431B1 (ko) | 신규 마우스 시엑스시 케모카인 수용체 | |
AU2004205143A1 (en) | Uses of a chemokine receptor for inhibiting HIV-1 infection | |
Howie et al. | A functional, discontinuous HIV‐1 gp120 C3/C4 domain‐derived, branched, synthetic peptide that binds to CD4 and inhibits MIP‐1α chemokine binding | |
AU776239B2 (en) | Method for preventing HIV-1 infection of CD4+ cells | |
MXPA98010425A (en) | Uses of a chemiocine receiver to inhibit theinfection with human immunodeficiency viruses | |
AU2004233505B2 (en) | Method for preventing HIV-1 infection of CD4+ cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP MX |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: CA |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 98501831 Format of ref document f/p: F |
|
122 | Ep: pct application non-entry in european phase |